Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.70 |
| ▸ | NPC1 | O15118 | 1/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.70 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.70 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.64 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.64 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.64 |
| ▸ | PLK1 | P53350 | 3/20 | 0.57 |
| ▸ | BRD4 | O60885 | 1/20 | 0.54 |
| ▸ | CDK9 | P50750 | 1/20 | 0.54 |
| ▸ | IKBKB | O14920 | 2/20 | 0.54 |
| ▸ | SYK | P43405 | 1/20 | 0.53 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.52 |
| ▸ | CDK1 | P06493 | 1/20 | 0.52 |
| ▸ | CDK4 | P11802 | 1/20 | 0.52 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.52 |
| ▸ | CCND1 | P24385 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4732832 | 0.81 | PLK1 (0.74) | MEN1KMT2APIK3CGPIK3CAPIK3CB | |
| SCHEMBL27116705 | 0.81 | PIK3CG (0.73) | MEN1KMT2ACDK5NPC1RAB9A | |
| SCHEMBL1667472 | 0.80 | MEN1 (0.75) | MEN1KMT2ACDK5NPC1RAB9A | |
| SCHEMBL27116598 | 0.79 | PIK3CG (0.83) | MEN1KMT2ACDK5NPC1RAB9A | |
| SCHEMBL10977837 | 0.79 | PIK3CG (0.78) | MEN1KMT2ACDK5NPC1RAB9A | |
| SCHEMBL7466239 | 0.78 | ACVR1 (0.72) | MEN1KMT2ACDK5NPC1RAB9A | |
| SCHEMBL4735284 | 0.78 | PLK1 (0.70) | MEN1KMT2ACDK5NPC1RAB9A | |
| SCHEMBL2942460 | 0.78 | PIK3CG (0.76) | MEN1KMT2ACDK5NPC1RAB9A | |
| SCHEMBL4733865 | 0.77 | MEN1 (0.60) | MEN1KMT2ACDK5NPC1RAB9A | |
| SCHEMBL5401497 | 0.77 | MEN1 (0.62) | MEN1KMT2ACDK5NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080153822-A1 | Methods of treating pain | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-06-26 | — | — | US | claimed |
| WO-2008065155-A1 | CDK INHIBITORS FOR TREATING PAIN | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-06-05 | — | — | WO | claimed |
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | claimed |
| JP-2007500179-A | — | — | 2007-01-11 | — | — | JP | claimed |
| EP-1648875-A1 | 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS | Cyclacel Limited (GB) | 2006-04-26 | — | — | EP | claimed |
| WO-2005012262-A1 | 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2005-02-10 | — | — | WO | claimed |
| US-20080153822-A1 | Methods of treating pain | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-06-26 | — | — | US | disclosed |
| US-20080153822-A1 | Methods of treating pain | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-06-26 | — | — | US | disclosed |
| US-20080153822-A1 | Methods of treating pain | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-06-26 | — | — | US | disclosed |
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| EP-1648875-A1 | 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS | Cyclacel Limited (GB) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005012262-A1 | 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005012262-A1 | 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | GRK3, NCOR1, GRM3 | MEN1 3759/4885KMT2A 1131/4885CDK5 737/4885 |
| US-20080153822-A1 | Methods of treating pain | OPRL1, ACHE, OPRK1 | MEN1 3807/4885KMT2A 2447/4885CDK5 2587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.